Fresenius Kabi Oncology’s (FKOL) promoter entity Fresenius Kabi (Singapore) (FKSL) is planning to delist its Indian arm through acquiring 19% stake held by the public. FKSL intends to pay an indicative price of upto Rs 130 per share to acquire the scrips offered to it in the delisting offer.
Fresenius Kabi (Singapore) holds 81% of the total stake in the Indian arm.
Fresenius Kabi Oncology manufactures Active Pharmaceutical Ingredients (API) for anti cancer, drug intermediate, calcium regulator, muscle relaxant, Analgesic and many more.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1654.30 |
| Dr. Reddys Lab | 1216.90 |
| Cipla | 1229.00 |
| Zydus Lifesciences | 931.10 |
| Lupin | 2316.55 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: